BioSpace News Archive

STRATA Skin Sciences, Inc. announced that it has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced its 2024 full-year financial guidance and provided a business update.

ALX Oncology Holdings Inc. announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024.

Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) today announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical needs in both rare and common disease populations.

Ardelyx, Inc. today announced it will host a live event and webcast on Monday, January 8, 2024, at 7:00 p.m. ET / 4:00 p.m. PT.

Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

The National Advisory Committee on Immunization’s (NACI) annual Statement on Seasonal Influenza Vaccine for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent (Influenza Vaccine) among the preferential influenza vaccines to protect adults 65 years of age and older against influenza.

IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of a study titled “Piezo1 facilitates optimal T cell activation during tumor challenge” in the highly influential peer-reviewed journal OncoImmunology.

Alcyone Therapeutics Inc. announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System.